• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Lundbeck's Mid-Stage Alzheimer's Success


Patients who took Lundbeck's experimental Alzheimer's drug achieved significant improvement in cognition, according to trial data from the Danish drugmaker.

Patients who took Lundbeck’s experimental Alzheimer’s drug achieved significant improvement in cognition, according to trial data from the Danish drugmaker.

Lu AE58054, which just completed a Phase 2 clinical trial, was tried in combination with donepezil on 278 patients suffering from moderate Alzheimer’s. The study achieved its main target of improved cognitive function, as well as showed positive trends in secondary endpoints, including activities of daily living.

"These results are very encouraging, and we are now evaluating how to best proceed with the development of Lu AE58054," said Executive Vice President Anders Gersel Pedersen, head of Research & Development at Lundbeck, in a statement. "We believe that there is a strong need for better treatments for patients with Alzheimer's disease, and Lundbeck sees Lu AE58054 as a potential new treatment option for this devastating disease."

Lundbeck’s stock has been up since the positive news of the trial results and is up 14% year-to-date.

Click to enlarge


The race for an Alzheimer’s drug is intense. Johnson & Johnson is partnered with Pfizer on bapineuzumab, which is in a late-stage program. Eli Lilly’s solanezumab is in a final stage trial as well. Lastly, Roche’s gantenerumab is only at the second stage of trials.

Plus, Roche’s crenezumab was chosen to be part of the government’s National Alzheimer’s Plan. The company was granted $16 million to try the drug on people with no signs of dementia to see if early intervention can prevent or slow the disease.

However, the Alzheimer’s field is full of failures, including a former Lilly drug, semagecestat. And two-thirds of analysts surveyed by ISI Group expect J&J and Pfizer’s bapineuzumab and Lilly’s solanezumab to fail.

Read more:

Lundbeck Touts Success of Mid-Stage Alzheimer’s Study

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice